← SGLT2 inhibitors × kidney outcomes

TrialDiabetologia2021

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.

Taha Sen et al.PubMed ↗Full text ↗Publisher ↗

What moved togetherboth groups pooled, not the treatment’s effect

Correlation · may be no link

No clear link with kidney outcomes

−20%−30% to +0%

Bigger than 4 in 10 on the map

As reported

HR 0.8, 95% CI 0.70–1.00

One number in the abstract

the abstract, start to end

… a lower risk of the kidney outcome (HR 0.8 [95% CI 0.7, 1.0; p = 0.02] and …

← favours treatmentfavours comparator →
could be chance
Kidney outcomes
HR 0.80.70–1.00
SGLT2 inhibitorsKidney outcomes
1 / 3

53 papers cite it

2021
2022
2023
2024
2025
2026
this papertrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 34415356